ArticleBMC pulmonary medicine2026
Persistently low blood eosinophils identify a high-risk phenotype in COPD.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBlood eosinophil count (BEC) is used to guide COPD therapy, yet its longitudinal stability and prognostic relevance remain debated. We investigated BEC variability and the clinical implications of eosinophil trajectories.
methodsStable COPD patients (n = 471) were prospectively recruited in Singapore from 2013 to 2025. BEC stability was assessed using paired baseline and 1-year measurements. Patients were classified as persistently low (LL), persistently high (HH), or variable (VAR) based on a 0.15 × 10⁹/L threshold across 1 year period. Associations with exacerbations and mortality were examined using multivariable regression, with findings validated in an independent cohort from China (n = 66).
resultsAmong 471 patients, low baseline BEC (< 0.15 × 10⁹/L) was associated with worse lung function, higher symptom burden, and increased unadjusted mortality (p < 0.05). Paired BEC measurements (n = 176) showed moderate reproducibility (intraclass correlation coefficient = 0.423), indicating within-individual variability. Trajectory analysis revealed that compared to the LL group, both HH and VAR groups had significantly lower historical exacerbation rates. During one-year follow-up, the LL group experienced higher rates of hospitalized exacerbations. Kaplan-Meier analysis demonstrated a trend toward increased mortality in the LL group (log-rank p = 0.066). In multivariable Cox models, the VAR group had a significantly lower mortality risk compared with LL (HR = 0.465, p = 0.031), while the HH group showed a non-significant trend toward reduced mortality (HR = 0.637, p = 0.171). These patterns of higher exacerbation risk and trend toward higher mortality in the LL phenotype were consistent in the validation cohort.
conclusionsPersistently low BEC identifies a high-risk phenotype associated with increased exacerbations and trend toward poor prognosis, a finding corroborated in an independent cohort, supporting the value of repeated assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.